Skip to main content
Journal cover image

Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.

Publication ,  Journal Article
Mahaffey, KW; Granger, CB; Toth, CA; White, HD; Stebbins, AL; Barbash, GI; Vahanian, A; Topol, EJ; Califf, RM
Published in: J Am Coll Cardiol
December 1997

OBJECTIVES: This study sought to evaluate the incidence of ocular hemorrhage in patients with and without diabetes after thrombolytic therapy for acute myocardial infarction. BACKGROUND: Ocular hemorrhage after thrombolysis has been reported rarely. However, there is concern that the risk is increased in patients with diabetes. In fact, diabetic hemorrhagic retinopathy has been identified as a contraindication to thrombolytic therapy without clear evidence that these patients have an increased risk for ocular hemorrhage. METHODS: We identified all suspected ocular hemorrhages from bleeding complications reported in patients enrolled in the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I trial. Additional information was collected on a one-page data form. We compared the incidence and location of ocular hemorrhages in patients with and without diabetes. RESULTS: There were 40,899 patients (99.7%) with information about diabetic history and ocular bleeding. Twelve patients (0.03%) had an ocular hemorrhage. Intraocular hemorrhage was confirmed in only one patient. There were 6,011 patients (15%) with diabetes, of whom only 1 had an ocular hemorrhage (eyelid hematoma after a documented fall). The upper 95% confidence intervals for the incidence of intraocular hemorrhage in patients with and without diabetes were 0.05% and 0.006%, respectively. CONCLUSIONS: Ocular hemorrhage and, more important, intraocular hemorrhage after thrombolytic therapy for acute myocardial infarction is extremely uncommon. The calculated upper 95% confidence interval for the incidence of intraocular hemorrhage in patients with diabetes was only 0.05%. We conclude that diabetic retinopathy should not be considered a contraindication to thrombolysis in patients with an acute myocardial infarction.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

December 1997

Volume

30

Issue

7

Start / End Page

1606 / 1610

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Streptokinase
  • Risk Factors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Heparin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mahaffey, K. W., Granger, C. B., Toth, C. A., White, H. D., Stebbins, A. L., Barbash, G. I., … Califf, R. M. (1997). Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol, 30(7), 1606–1610. https://doi.org/10.1016/s0735-1097(97)00394-x
Mahaffey, K. W., C. B. Granger, C. A. Toth, H. D. White, A. L. Stebbins, G. I. Barbash, A. Vahanian, E. J. Topol, and R. M. Califf. “Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries.J Am Coll Cardiol 30, no. 7 (December 1997): 1606–10. https://doi.org/10.1016/s0735-1097(97)00394-x.
Journal cover image

Published In

J Am Coll Cardiol

DOI

ISSN

0735-1097

Publication Date

December 1997

Volume

30

Issue

7

Start / End Page

1606 / 1610

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Streptokinase
  • Risk Factors
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Incidence
  • Humans
  • Heparin